Virpax Pharmaceuticals Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Jay Dhaliwal

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	less than a year

Recent management updates

Recent updates

CEO

Jay Dhaliwal (35 yo)

less than a year

Tenure

Mr. Jatinder Dhaliwal, also known as Jay, serves as Chief Executive Officer of Virpax Pharmaceuticals, Inc since October 06, 2024 and serves as its Director since October 06, 2024. He serves as a Director...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Sheila Mathias	Chief Scientific Officer	3.8yrs	US$498.00k	0% $ 0
Jatinder Dhaliwal	CEO & Director	less than a year	no data	no data
Usama Chaudhry	Chief Financial Officer	less than a year	no data	no data

0.3yrs

Average Tenure

35yo

Average Age

Experienced Management: VRPX's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Jatinder Dhaliwal	CEO & Director	less than a year	no data	no data
Judy Su	Independent Director	less than a year	no data	no data
Katharyn Field	Independent Director	less than a year	no data	no data
Esha Randhawa	Independent Director	less than a year	no data	no data
Jaydriane Panis	Director	less than a year	no data	no data

0.5yrs

Average Tenure

37yo

Average Age

Experienced Board: VRPX's board of directors are not considered experienced ( 0.5 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/06 23:29
End of Day Share Price	2025/01/06 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Virpax Pharmaceuticals, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jason McCarthy	Maxim Group
Nazibur Rahman	Maxim Group
Ashok Kumar	ThinkEquity LLC

Virpax Pharmaceuticals Management

Management criteria checks 0/4

Key information

Recent management updates

High number of new and inexperienced directors

Virpax Pharmaceuticals, Inc. Announces Resignation of Gary Herman as Member of the Board of Directors and from All Committees

High number of new and inexperienced directors

Virpax Pharmaceuticals, Inc. Announces CEO Changes

High number of new and inexperienced directors

Less than half of directors are independent

Recent updates

High number of new and inexperienced directors

Virpax Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $6 million.

Virpax Pharmaceuticals, Inc. Announces Resignation of Gary Herman as Member of the Board of Directors and from All Committees

High number of new and inexperienced directors

Virpax Pharmaceuticals Receives Letter from Nasdaq Regarding Non-Compliance with Nasdaq’s Independent Director and Audit Committee Requirements under Listing Rules 5605(b)(1) and 5605(c)(2)

Virpax Pharmaceuticals Receives a Letter from the Nasdaq Stock Market

Virpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur

Virpax Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $5.041561 million.

Virpax Pharmaceuticals, Inc. Announces CEO Changes

Virpax Pharmaceuticals, Inc. Receives A Delist Determination Letter from the Listing Qualifications Department of the Nasdaq Stock Market

High number of new and inexperienced directors

Nasdaq Grants Extension Through September 30 to Virpax Pharmaceuticals to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

Virpax Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

Virpax Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price

New major risk - Revenue and earnings growth

Less than half of directors are independent

Virpax Pharmaceuticals, Inc. Announces the Changes to Its Board of Directors

Virpax Pharmaceuticals Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

New major risk - Shareholder dilution

Virpax Pharmaceuticals, Inc., Annual General Meeting, Jul 29, 2024

Virpax Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $2.25 million.

Virpax Pharmaceuticals, Inc. Announces Results of Maximum Tolerated Dose Study for Probudur

Virpax Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

Virpax Pharmaceuticals Receives Non-Compliance Letter from Nasdaq Related to Listing Rule 5550(b)(1)

New major risk - Financial position

Virpax Pharmaceuticals Regains Compliance with Listing Rule 5550(a)(2)

Price target decreased by 50% to US$2.00

Price target decreased by 50% to US$2.00

Virpax Pharmaceuticals, Inc. Announces CEO Changes

Virpax Pharmaceuticals, Inc. Announces CEO Changes

Virpax Pharmaceuticals, Inc. announced delayed 10-Q filing

Virpax Pharmaceuticals Announces Envelta Remains on Track for Trial in Humans Following FDA Review

Nasdaq Grants Virpax Pharmaceuticals’ Request for 180-Day Extension to Regain Compliance with the Minimum Bid Price Requirement

Novvae Pharmaceuticals Announces Executive Appointments

Virpax Pharmaceuticals, Inc Announces the Formation of Novvae™ Pharmaceuticals

Virpax Pharmaceuticals, Inc. Announces Update on Litigation

Virpax Pharmaceuticals, Inc. Files Provisional Patent Application for NSAID Formulation and Method

New major risk - Market cap size

Virpax Pharmaceuticals, Inc. Announces CFO Changes

New minor risk - Share price stability

Virpax Pharmaceuticals, Inc., Annual General Meeting, Jul 24, 2023

Virpax Pharmaceuticals, Inc. Appoints Barbara Ruskin as Class I Director

Virpax Pharmaceuticals, Inc. Announces Positive Preclinical Toxicology Results in Support of Molecular Envelope Technology

Virpax Pharmaceuticals Receives A Written Notice from Nasdaq Regarding Bid Price Requirement

Virpax Pharmaceuticals, Inc. Reports on FDA Pre-IND Response for NobrXiol™ (Formerly Vrp324)

Virpax Pharmaceuticals GAAP EPS of -$0.50 misses by $0.06

Virpax Pharmaceuticals, Inc. Pursues OTC Medical Device Pathway for AnQlar

Virpax Pharmaceuticals, Inc Will Pursue Direct to OTC Pathway for Epoladerm™ for Pain Associated with Osteoarthritis

Virpax Pharmaceuticals, Inc., Annual General Meeting, Jul 25, 2022

Chairman & CEO recently bought US$102k worth of stock

Virpax Pharmaceuticals, Inc. Completes Initial Preclinical Studies for VRP324

Virpax Pharmaceuticals, Inc. Reports Favorable Preclinical Safety Data for Envelta™ for the Treatment of Acute and Chronic Pain

Virpax Pharmaceuticals, Inc. Successfully Completes Preclinical Dermal Safety Studies for Epoladerm

Virpax Pharmaceuticals, Inc. Announces Clinical Trial Site in Canada for First in Human Study of Epoladerm for Pain Associated with Osteoarthritis of Knee

Virpax Pharmaceuticals, Inc. Reports Successful Results of Toxicology and Pharmacokinetic Study for Epoladerm™

Chairman & CEO recently bought US$100k worth of stock

Virpax Pharmaceuticals, Inc. (NasdaqCM:VRPX) acquired Exclusive worldwide rights of Nanomerics Ltd.

Virpax Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $40.02 million.

Virpax: Targeting Pain At Its Source

Virpax Pharmaceuticals, Inc Announces That the Investigational New Drug Application Enabling Studies for Envelta

Virpax Pharmaceuticals shares surge on Envelta IND update

Virpax(R) Pharmaceuticals Inc., Virpax Begins Ind Enabling Studies of Envelta(Tm)

Virpax Pharmaceuticals, Inc. has completed an IPO in the amount of $18 million.

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members